<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682250</url>
  </required_header>
  <id_info>
    <org_study_id>FRYPOT</org_study_id>
    <nct_id>NCT03682250</nct_id>
  </id_info>
  <brief_title>Electrocardiographic Modifications and Spontaneous Hypoglycemic Episodes in Type 1 Diabetes</brief_title>
  <official_title>Electrocardiographic Modifications During Spontaneous Hypoglycemic Episodes in Patients With Type 1 Diabetes at High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The population of type 1 diabetes patients with cardiovascular disease is increasing and this
      study aims to explore the electrocardiographic changes that are associated with spontaneous
      hypoglycemia in this type of population. More precisely, this study will investigate if these
      modifications are of the same nature as those already observed in different populations
      (patients with type 2 diabetes) to see the pro-arrhythmogenic impact of hypoglycemia in
      patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QT intervals corrected for heart rate</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time between 4.0 and 10.0 mmol/L</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time below 3.5 mmol/L</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes with a high cardiovascular risk</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre Pro</intervention_name>
    <description>A FreeStyle Libre Pro will be used to identify hypoglycemic episodes</description>
    <arm_group_label>Patients with type 1 diabetes with a high cardiovascular risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter monitor</intervention_name>
    <description>A Holter monitor will be used to measure heart's activity</description>
    <arm_group_label>Patients with type 1 diabetes with a high cardiovascular risk</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with type 1 diabetes presenting a high cardiovascular risk
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years old;

          -  Be able to give informed consent;

          -  Diagnosis of type 1 diabetes for ≥ 6 months;

          -  Treated with intensive insulin therapy (multiple injections of insulin or insulin
             pump)

        AND EITHER

          -  A history of CV disease defined as: 1) Established diagnosis of atherosclerotic
             coronary artery disease (example: previous history of infarction); 2) Previous
             cerebral Vascular Stroke or Transient Ischemic Accident; 3) Anterior revascularization
             of the coronary arteries, carotid artery or peripheral arteries; 4) At least one
             coronary stenosis, carotid artery or lower extremity arteries &gt; 50%; 5) History of
             symptomatic coronary heart disease confirmed with hospitalization or a positive stress
             test result or by any cardiac imaging result, or unstable angina with changes observed
             at the ECG; 6) Asymptomatic cardiac ischemia confirmed by a nuclear imaging test, an
             exercise test, a dobutamine stress echo; 7) NYHA II-III class chronic heart failure;
             8) Amputation of limb or foot due to circulatory insufficiency.

          -  Or more than 20 years duration of T1D and at least 2 of the following risk factors or
             associated condition: 1) Chronic renal failure eGFR &lt;60 ml / min / 1.73 m2); 2)
             Presence of micro or macro-albuminuria (albumin / creatinine ratio &gt; 2); 3)
             Hypertension or treatment for hypertension; 4) Hyperlipidemia or treatment for
             hypolipemia; 5) Abdominal obesity (Waist circumference&gt; 94 cm for men and &gt; 80 cm for
             women); 6) Smoking ; 7) Significant retinopathy (pre-proliferative, proliferating,
             laser or intravitreous injection); 8) Body mass index &gt; 30 kg /m2; 9) Erectile
             dysfunction; 10) Left ventricular hypertrophy; 11) Positive family history of early
             MCAS (H &lt; 55 years old and F &lt; 65 years old)

        Exclusion Criteria:

          -  Definitive criteria: 1) QRS &gt; 120 ms on the baseline ECG; 2) Presence of atrial
             fibrillation at inclusion; 3) Current intake of any drug that may prolong QT according
             to the judgment of the investigator and the update of the list available on
             www.professionsante.com.

          -  Transient criteria (the patient can be included once the anomaly is corrected): 1)
             Hypokalemia (&lt; 3.5 mmol/L); 2) Hypocalcemia (ionized calcium &lt; 1.10 mmol/L); 3)
             Hypomagnesemia (&lt; 0.7 mmol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Rabasa-Lhoret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Remi Rabasa-Lhoret</last_name>
    <phone>1-514-987-5666</phone>
    <email>remi.rabasa-lhoret@ircm.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helene Mansaray</last_name>
    <phone>1-514-987-5500</phone>
    <phone_ext>3227</phone_ext>
    <email>mansarayh@yahoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remi Rabasa-Lhoret</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherches Cliniques de Montreal</investigator_affiliation>
    <investigator_full_name>Rémi Rabasa-Lhoret</investigator_full_name>
    <investigator_title>Full professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

